RecruitingNCT05802836

Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

Sponsor

Christoph Königs

Enrollment

100 participants

Start Date

Apr 26, 2023

Study Type

OBSERVATIONAL

Conditions

Severe Hemophilia A Severe Hemophilia A With Inhibitor Severe Hemophilia A Without Inhibitor

Summary

The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying no interventions for people with severe hemophilia a, severe hemophilia a with inhibitor, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERno interventions

no intervention, only 3 different patients groups

Locations(1)

University Hospital Frankfurt, Goethe University

Frankfurt am Main, Hesse, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05802836

Related Trials

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.

NCT0768489819 locations

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment

NCT0766390324 locations

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

NCT067036067 locations

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

NCT0593535818 locations

A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)

NCT059812741 location